<DOC>
	<DOCNO>NCT00502710</DOCNO>
	<brief_summary>This 5 arm study ass efficacy , pharmacokinetics , safety tolerability DPP-IV inhibitor compare placebo patient type 2 diabetes . Patients randomized receive DPP-IV ( 3 ) one 4 dos ( 12.5mg ) , placebo p.o . Patients receive metformin study continue dose metformin . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Dipeptidyl-peptidase IV ( DPP-IV ) RO4876904 Patients With Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes diagnose &gt; = 1 month screening ; drugnaive , pretreated maximum tolerate dose ( MTD ) metformin ; BMI 2545kg/m2 . type 1 diabetes ; antihyperglycemic medication metformin , weightlowering drug , last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>